Metraipolis › archive › dc_76ead72b6010
Understanding early HIV-1 rebound dynamics following antiretroviral therapy interruption: The importance of effector cell expansion — Europe PMC PMID:39074163
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/39074163
- DOI
- 10.1371/journal.ppat.1012236
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T16:55:04.077Z
- SHA-256 of the archived text
2d8c277d0300d1e80c5301a9b2d89b5a9515f8d2cf0cdb887bb261c167bac7fe- Stable URL of this page
https://metraipolis.com/documento/dc_76ead72b6010
How to cite
Understanding early HIV-1 rebound dynamics following antiretroviral therapy interruption: The importance of effector cell expansion — Europe PMC PMID:39074163 — Europe PMC (en), https://europepmc.org/article/MED/39074163 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_76ead72b6010 (Metraipolis archive dc_76ead72b6010, sha256 2d8c277d0300d1e80c5301a9b2d89b5a9515f8d2cf0cdb887bb261c167bac7fe)
BibTeX
@misc{dc76ead72b6010,
title = {Understanding early HIV-1 rebound dynamics following antiretroviral therapy interruption: The importance of effector cell expansion — Europe PMC PMID:39074163},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/39074163},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_76ead72b6010; sha256 2d8c277d0300d1e80c5301a9b2d89b5a9515f8d2cf0cdb887bb261c167bac7fe},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/39074163. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Most people living with HIV-1 experience rapid viral rebound once antiretroviral therapy is interrupted; however, a small fraction remain in viral remission for an extended duration. Understanding the factors that determine whether viral rebound is likely after treatment interruption can enable the development of optimal treatment regimens and therapeutic interventions to potentially achieve a functional cure for HIV-1. We built upon the theoretical framework proposed by Conway and Perelson to construct dynamic models of virus-immune interactions to study factors that influence viral rebound dynamics. We evaluated these models using viral load data from 24 individuals following antiretroviral therapy interruption. The best-performing model accurately captures the heterogeneity of viral dynamics and highlights the importance of the effector cell expansion rate. Our results show that post-treatment controllers and non-controllers can be distinguished based on the effector cell expansion rate in our models. Furthermore, these results demonstrate the potential of using dynamic models incorporating an effector cell response to understand early viral rebound dynamics post-antiretroviral therapy interruption. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLoS pathogens, 2024 (prima pubblicazione 2024-07-29). Identificativi: PMID 39074163 · PMCID PMC11309407 · DOI 10.1371/journal.ppat.1012236. Descrittori MeSH principali: HIV-1; HIV Infections; Viral Load. Pagina: https://europepmc.org/article/MED/39074163 — https://doi.org/10.1371/journal.ppat.1012236. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T15:19:26.791Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.